<DOC>
	<DOCNO>NCT01395992</DOCNO>
	<brief_summary>Participants complete 3-week trial P05691 ( NCT00764478 ) screen eligibility 26-week extension study continue treatment . The primary purpose trial evaluate long-term safety asenapine .</brief_summary>
	<brief_title>Long-Term Safety Extension Trial Asenapine Bipolar 1 Disorder Participants Who Completed Protocol P05691 ( P05692 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion criterion : Each participant must complete shortterm trial P05691 , judge investigator likely benefit continue treatment Each participant must demonstrate acceptable degree compliance trial medication , visit , requirement shortterm trial P05691 Exclusion criterion : A participant must adverse event clinically significant finding ( ) shortterm trial P05691 would prohibit subject 's continuation longterm extension trial A participant must newly diagnose discover psychiatric condition would exclude subject participation shortterm trial P05691 A participant must imminent risk selfharm harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>